Relative Bronchodilating effects of Formoterol when Administered via Symbicort pressurized metered-dose inhaler (pMDI) or Oxis Turbuhaler

Study identifier:SD-039-0729

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomized, multicenter, open-label, active-controlled, single-dose, 5-period, incomplete block, cross-over study to evaluate the relative bronchodilating effects of formoterol when administered via Symbicort pMDI or Oxis Turbuhaler to adults with stable asthma

Medical condition

stable asthma

Phase

Phase 2

Healthy volunteers

Study drug

budesonide/formoterol, formoterol

Sex

All

Actual Enrollment

175

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Oct 2002

Primary Completion Date: -

Study Completion Date: 01 May 2003

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2011 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: 1	-
Active Comparator: 2	-

Documents available

Trial Results Summaries
Available here

Contacts

Contact

null AstraZeneca Clinical Study Information

800-236-9933

[email protected]

Investigators

Principal Investigator

Michael E Ruff

Pharmaceutical Research & Consulting Inc